Adhera Therapeutics, Inc.
Adhera Therapeutics, Inc. (ATRX) Stock Ownership
Latest 13F position summary is not yet available — breakdown and tables fill in after filings publish (typically ~45 days after quarter end).
SEC 13F · FMP · ATRX · as of —
Ownership Breakdown
Institutional data for this period is not yet available. SEC Form 13F filings are typically published 45 days after quarter end.
No institutional data available for this period.
Insider Buying vs Selling
ATRX insider trading · insider activity
Source: SEC Form 4
Insiders have been net buyers of shares recently. Selling may be driven by pre-scheduled Rule 10b5-1 plans rather than negative sentiment.
0
Buy transactions
0
Sell transactions
0.00
Buy/Sell ratio
$0M
Total disposed
Recent Insider Transactions
Showing 10 most recent · Common Stock only
| Name · Role | Date | Type | Shares | Price | Value | After Trans. | Filing |
|---|---|---|---|---|---|---|---|
Stanley Rhonda L. SVP Finance & Accounting | Nov 1, 2019 | Award | 350,000 | $0.09 | $31.5K | 350.0K | Form 4 ↗ |
Phelan Nancy R. CEO and Secretary | Apr 4, 2019 | Award | 1,500,000 | $0.37 | $555.0K | 1.50M | Form 4 ↗ |
Teague Robert Eric Chief Financial Officer | Jan 15, 2019 | Award | 100,000 | $0.32 | $32.0K | 100.0K | Form 4 ↗ |
Trieu Vuong
| Oct 1, 2018 | D-Return | 500,000 | $0.50 | $250.0K | 612.7K | Form 4 ↗ |
Moscato Robert Jr. Chief Executive Officer | Jul 12, 2018 | Purchase | 300,000 | $0.55 | $165.0K | 300.0K | Form 4 ↗ |
Moscato Robert Jr. Chief Executive Officer | Jul 12, 2018 | Purchase | 40 | $0.50 | $20 | 40 | Form 4 ↗ |
Emerson Erik Chief Commercial Officer | Jul 10, 2018 | Award | 1,125,000 | $0.66 | $742.5K | 1.13M | Form 4 ↗ |
Hacksell Uli director | Jul 10, 2018 | Award | 1,000,000 | $0.66 | $660.0K | 1.00M | Form 4 ↗ |
Moscato Robert Jr. Chief Executive Officer | Jul 10, 2018 | Award | 1,500,000 | $0.66 | $990.0K | 1.50M | Form 4 ↗ |
Ramelli Joseph W. | May 2, 2018 | Award | 100,000 | $0.98 | $98.0K | 100.0K | Form 4 ↗ |
Source: /insider-trading/search (FMP stable). Buy/Sell direction: acquisitionOrDisposition A=Buy, D=Sell. RSU vesting (M-Exempt) excluded from sentiment bar. All data from SEC EDGAR public filings.
About institutional & insider ownership
Adhera Therapeutics, Inc. (ATRX) is primarily owned by institutional investors, who hold approximately — of total shares outstanding. Company insiders own approximately —, while retail and public investors account for the remaining —.
A total of 0 institutional investors currently hold ATRX stock, with a combined institutional value of approximately $0 as of the most recent 13F filing period.
Frequently asked questions
ATRX ownershipAdhera Therapeutics, Inc. (ATRX) is primarily owned by institutional investors, who hold approximately — of shares. The largest shareholder is — with a — stake. Company insiders hold —. Data sourced from SEC Form 13F as of —.